Data from multiple sources - Curated by Toby Galbraith - Last updated 04 January 2017

Latest news articles

Added 23 days ago Drug news

Phase III pivotal trial results for SB 204 (nitric oxide) in treatment of acne vulgaris shows some benefits- Novan

Novan announced top-line results from the Company’s two, replicate Phase III pivotal clinical trials for SB 204 (nitric oxide) in...

Added 2 months ago Drug news

Restylane (dermal filler) given new approvals by FDA for nasolabial folds- Galderma

Galderma has received FDA approval of two new products for the treatment of nasolabial folds (NLF) or "laugh lines," in...

Added 2 months ago Drug news

Phase III results for Nucala (mepolizumab) in patients with relapsing and refractory Eosinophilic Granulomatosis with Polyangiitis- GlaxoSmithKline

GlaxoSmithKline has announced that both co-primary endpoints and all secondary endpoints were met in a pivotal phase III study investigating...

View all news articles

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria

Visit Chronic Spontaneous Urticaria (CSU)

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress 2015

Visit IL-17A in Psoriasis


See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more

Visit Psoriasis

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians

Visit Chronic Obstructive Pulmonary Disease (COPD)


Adalimumab for treating moderate to severe hidradenitis suppurativa

Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

Added 6 days ago

Guidelines of care for the management of psoriasis and psoriatic arthritis

Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.

Added 8 days ago

Canadian Guidelines for the Management of Plaque Psoriasis 2009

Since the publication of the 2009 Canadian Guidelines for the Management of Plaque Psoriasis, significant advances have been made in determining the role of T cells in inflammatory and autoimmune diseases. 

Added 8 days ago

View all guidelines

Journal articles

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.

The interleukin-17 cytokine family plays a central role in psoriasis pathogenesis.

Added 4 days ago

Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.

Brodalumab (KHK4827 or AMG 827) is a human monoclonal antibody that binds to the human interleukin (IL)-17 receptor A and blocks the biological activities of IL-17A, IL-17F...

Added 4 days ago

Prevalence and clinical characteristics of psoriasis in spondyloarthritis: a descriptive analysis of 275 patients.

To assess the prevalence of psoriasis among a cohort of patients with spondyloarthritis (SpA), to describe the clinical characteristics of psoriasis and associations with other manifestations.

Added 4 days ago

View all journal articles

Clinical trials

A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent...

Added 15 hours ago

A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis

The safety of ixekizumab (LY2439821) and any side effects that might be associated with it....

Added 16 hours ago

A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period

This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.

Added 4 days ago

View all clinical trials